Why is Hester Bios falling/rising?

As of 30-Oct, Hester Biosciences Ltd is experiencing a decline in its stock price, currently at 1,599.60, reflecting a decrease of 17.7 points or 1.09%. The stock has underperformed its sector by 0.75% today and has been on a consecutive downward trend for the last six days, resulting in a total decline of 7.64% during this period. Over the past week, the stock has dropped by 6.61%, and it has significantly underperformed the benchmark Sensex, which has only decreased by 0.18%. Despite reporting a substantial growth in net profit of 145.1% and positive results for the last five consecutive quarters, the stock's long-term growth prospects appear weak, with net sales and operating profit growing at only 11.90% and 5.48% annually over the last five years, respectively. Furthermore, the company's high Debt to EBITDA ratio of 3.49 times raises concerns about its ability to service debt, contributing to the negative sentiment surrounding the stock.
In the broader market context, Hester Biosciences has shown poor performance relative to the Sensex, with a year-to-date decline of 33.15% compared to the benchmark's gain of 8.02%. This stark contrast highlights the stock's struggles in both short-term and long-term performance, as it has underperformed the BSE500 over the past three years, one year, and three months. Additionally, the lack of domestic mutual fund investment, which stands at 0%, may indicate a lack of confidence in the company's valuation and business prospects, further impacting investor sentiment negatively.